A Randomized, Placebo-controlled Clinical Trial of Teneligliptin as Quadruple Oral Combination Therapy for Type 2 DM After Failure of an Oral Triple Anti-diabetic Regimen

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT04446026

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04446026
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04446026. Randomized; double masking; primary purpose treatment. Start 2020-07-08 (actual); primary completion 2020-12-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Randomized, Placebo-controlled Clinical Trial of Teneligliptin as Quadruple Oral Combination Therapy for Type 2 DM After Failure of an Oral Triple Anti-diabetic Regimen
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
teneligliptin
Intervention (Drug)
Placebo
Lead sponsor
Yonsei University (class: other)

Record details

Record id
cardio:ct-nct04446026
Content hash
848e37a6f2a10a0bca7a05e96074f01129c256999437cb0a9eaab3e08a68b87f